Middle East & Africa ECMO Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Modality (Venoarterial ECMO, Venovenous ECMO, and Arteriovenous ECMO), Application (Respiratory and Cardiology), and Age Group (Adults, Pediatrics, and Neonates)
The MEA ECMO market is expected to grow from US$ 29.74 million in 2022 to US$ 33.54 million by 2028. It is estimated to record a CAGR of 2.0% from 2022 to 2028.
Growing Adoption of ECMO in Lung Transplantation Procedures Drives MEA ECMO Market Growth
Lung transplantation is a life-saving treatment option for patients suffering from end-stage lung diseases, such as COPD, Idiopathic pulmonary fibrosis (IPF), and cystic fibrosis, to improve the quality of life.ECMO is a versatile tool used in all lung transplantation phases, such as preoperative, intraoperative, and postoperative periods.
It acts as a bridge for a patient undergoing lung transplantation.Therefore, the adoption of ECMO during lung transplantation is growing rapidly to manage patients with life-threatening lung diseases.
Primary graft dysfunction (PGD) is the leading cause of death after a lung transplant.ECMO is used penultimately in treating PGD post lung transplantation.
Thus, the demand for ECMO equipment is growing for treating patients suffering from PGD.
MEA ECMO Market Overview
The MEA ECMO Market is segmented into the UAE, Saudi Arabia, South Africa, and the Rest of MEA.South Africa holds the largest market share in the MEA ECMO market during forecast period.
South Africa faces a burden of chronic cardiovascular diseases, including high hypertension and cardiac arrest.The country is experiencing an increasing burden of cardiovascular diseases, including coronary heart disease (CHD) and stroke.
According to WHO, it is estimated that the rate of premature death due to CVD amongst South African adults is projected to increase by 41% between 2000 and 2030.Moreover, in South Africa, stroke is a leading cause of death and disability.
The burden of stroke is expected to increase in the coming years as the population is experiencing a rapid epidemiological transition with increased exposure to and development of stroke risk factors, together with the aging of the population. Healthcare facilities in South Africa are developing and adopting the latest technologies to offer better treatments and diagnoses. Although the region remains highly exposed to political uncertainty, medical device exports will gain from accelerated economic growth in Sub-Saharan Africa, which will be aided by increased commodity prices and improved investor enthusiasm. In Sub-Saharan Africa, South Africa is the key business center for the medical device industry. A large percentage of medical device and lab equipment exports go to other African countries, with 12 African countries among the top 20 export destinations. Thus, owing to the above-mentioned factors, the country is expected to provide an opportunistic scenario for the ECMO market growth in South Africa during the forecast period.
MEA ECMO Market Revenue and Forecast to 2028 (US$ Million)
MEA ECMO Market Segmentation
The MEA ECMO market is segmented based on modality, application, age group, and country.
Based on modality, the MEA ECMO market is segmented into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment held the largest market share in 2022.
Based on application, the MEA ECMO market is bifurcated into respiratory and cardiology. The respiratory segment held a larger market share in 2022.
Based on age group, the MEA ECMO market is segmented into adults, pediatrics, and neonates. The adults segment held the largest market share in 2022.
Based on country, the MEA ECMO market has been categorized into the UAE, Saudi Arabia, South Africa, and the Rest of MEA. Our regional analysis states that South Africa dominated the market in 2022.
ABIOMED Inc, Braile Biomedica, Fresenius Medical Care AG & Co KGaA, Getinge AB, LivaNova Plc, Medtronic Plc, MicroPort Scientific Corporation, Nipro Medical Corporation, and Terumo Group are the leading companies operating in the MEA ECMO market.